Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Trabectedin

            Therapeutic Area: Oncology Product Name: Yondelis

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: STADA Arzneimittel

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement November 17, 2020

            Details:

            PharmaMar has granted to STADA a license to market the Yondelis® (trabectedin) marine-derived cancer treatment in 15 Middle East-North Africa countries. Yondelis® is marketed in several MENA countries for the treatment of soft tissue sarcoma and relapsed ovarian cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lurbinectedin

            Therapeutic Area: Oncology Product Name: Zepzelca

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Jazz Pharmaceuticals

            Deal Size: $7.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement October 15, 2020

            Details:

            PharmaMar and Jazz Pharma have entered into an amended and restated license agreement of the US lurbinectedin license agreement signed in December 2019 for the purpose of granting Jazz an exclusive license for Zepzelca™ (lurbinectedin) in Canada.